Ai Feedback
Exact(7)
Monotherapy with single cytotoxic drugs achieves modest objective response rates, seldom reaching 30%.
Currently, only one drug, sorafenib, is FDA approved for the treatment of advanced hepatocellular carcinoma (HCC), achieving modest objective response rates while still conferring an overall survival benefit.
Peptide receptor radionuclide therapy (PRRT) is well established as an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs) delivering modest objective response rates but notable symptomatic and probable survival benefits [1] [3].
Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors, several studies showed encouraging results in terms of prolongation of the time to progression, disease stabilization, and survival.
Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors (RECIST) [ 111], several studies showed encouraging results in terms of prolongation of the time to progression (TTP), disease stabilization (DS), and survival.
Despite of only modest objective response rates according to the Response Evaluation Criteria in Solid Tumors (RECIST) [ 44], several studies showed encouraging results in terms of prolongation of the time to progression (TTP), disease stabilization (DS), and survival.
Similar(53)
Toxicity was moderate, however, also treatment results were observed with only modest subjective and objective response rates; on the other hand, survival from relapse was remarkable at 13.7 months.
In the last decade, several small phase II trials of chemotherapeutics/targeted therapies for locally recurrent/metastatic SACC have yielded modest success, with objective response rates of 0 20%, stable disease (SD) rates of 20 87%, and median overall survival of 6 27 months [ 2– 14].
Biochemical responses were modest, but two patients had objective response radiographically.
For these agents, the objective response rates are generally modest, ranging from 15%to50%0%.
In the latter study, the effect on survival and objective response rate was rather modest, reflecting the more advanced stage of the disease in such patients.
Related(16)
low objective response
limited objective response
small objective response
modest periosteal response
modest inflammatory response
modest transcriptional response
modest IFNγ response
modest elevated response
modest excitotoxic response
modest overall response
modest partial response
modest clinical response
modest initial response
modest antiplatelet response
modest angiogenic response
modest immune response
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com